{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T16:14:59Z","timestamp":1743264899543,"version":"3.33.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4322,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,11]]},"abstract":"<jats:sec>\n            <jats:title>Key points<\/jats:title>\n            <jats:p>1. Treatment responses are lower in immune compromised patients such as those with hepatitis C virus (HCV) disease following liver transplantation than in immune competent patients with HCV disease.<\/jats:p>\n            <jats:p>2. Predictors of nonresponse, extrapolated from studies of immune competent patients, are overly represented in liver transplantation patients (high levels of HCV RNA and genotype 1 infection).<\/jats:p>\n            <jats:p>3. Tolerability of peginterferon plus ribavirin therapy is lower in transplant patients than in immune competent patients with HCV disease, in part because of a baseline renal insufficiency that increases the likelihood of ribavirin-associated anemia.<\/jats:p>\n            <jats:p>4. Clear recommendations regarding optimal treatment regimens for patients with posttransplantation HCV disease are problematic since there are few prospective, randomized, controlled trials that evaluated different treatment regimens.<\/jats:p>\n            <jats:p>5. If treatment is undertaken, baseline creatinine clearance should be measured and patients should be started on a dose of ribavirin of 400mg bid, or lower if renal function is impaired.<\/jats:p>\n            <jats:p>6. Tolerated peginterferon doses may be somewhat lower than for the standard immune competent patients. It is likely that lower doses will not greatly compromise response (1.0 ug\/kg\/week for peginterferon alfa 2b and 135 ug\/week for peginterferon alfa 2a).<\/jats:p>\n            <jats:p>7. Optimal treatment duration is unknown. In patients with an on-treatment response, at least 12 months of therapy is recommended.<\/jats:p>\n            <jats:p>8. More potent drugs with fewer toxicities are needed for patients with progressive posttransplantation liver disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1053\/jlts.2003.50259","type":"journal-article","created":{"date-parts":[[2003,10,29]],"date-time":"2003-10-29T17:35:56Z","timestamp":1067448956000},"page":"S109-S113","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration?"],"prefix":"10.1097","volume":"9","author":[{"given":"Teresa L.","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"BIB1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"BIB2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0168-8278(01)00179-9","volume":"35","author":"Berenguer","year":"2001","journal-title":"J Hepatol"},{"key":"BIB3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/jhep.2002.33993","volume":"36","author":"Berenguer","year":"2002","journal-title":"Hepatology"},{"key":"BIB4","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1053\/gast.2003.50095","volume":"124","author":"Samuel","year":"2003","journal-title":"Gastroenterology"},{"key":"BIB5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/jlts.2002.33968","volume":"8","author":"Narayanan Menon","year":"2002","journal-title":"Liver Transpl"},{"key":"BIB6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0168-8278(02)00109-5","volume":"37","author":"Lavezzo","year":"2002","journal-title":"J Hepatol"},{"key":"BIB7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"BIB8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"BIB9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0168-8278(02)80001-0","volume":"36","author":"Hadziyannis","year":"2002","journal-title":"J Hepatol"},{"key":"BIB10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"BIB11","doi-asserted-by":"crossref","first-page":"s128","DOI":"10.1053\/jhep.2002.36816","volume":"36","author":"Shiffman","year":"2002","journal-title":"Hepatology"},{"key":"BIB12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/jhep.2003.50278","volume":"38","author":"Berenguer","year":"2003","journal-title":"Hepatology"},{"key":"BIB13","doi-asserted-by":"crossref","first-page":"s185","DOI":"10.1002\/hep.1840360724","volume":"36","author":"Wright","year":"2002","journal-title":"Hepatology"},{"author":"Sulkowski","key":"BIB14","unstructured":"Changes in hemoglobin during interferon alfa-2b plus ribavirin combination therapy for chronic hepatitis C infection. J Viral Hepat (in press)."},{"key":"BIB15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00007691-200212000-00004","volume":"24","author":"Bruchfeld","year":"2002","journal-title":"Ther Drug Monit"},{"key":"BIB16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","volume":"34","author":"Lindsay","year":"2001","journal-title":"Hepatology"},{"key":"BIB17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2001.21747","volume":"33","author":"Reddy","year":"2001","journal-title":"Hepatology"},{"key":"BIB18","doi-asserted-by":"crossref","first-page":"295a","DOI":"10.1016\/S0168-8278(01)00291-4","volume":"36","author":"Shiffman","year":"2002","journal-title":"Hepatology D"},{"key":"BIB19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/jlts.2003.50062","volume":"9","author":"Gopal","year":"2003","journal-title":"Liver Transpl"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1053%2Fjlts.2003.50259","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-200311001-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T15:07:33Z","timestamp":1737731253000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-200311001-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.1053\/jlts.2003.50259","relation":{},"ISSN":["1527-6465"],"issn-type":[{"type":"print","value":"1527-6465"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}